Padlock Therapeutics investors accused Bristol Myers of avoiding making milestone payments promised under a 2016 deal.

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

The report provides a comprehensive... 12 déc 2024 Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Dr Dietmar Berger is set to join Gilead Sciences as Chief Medical Officer on 2 January 2025 – succeeding Dr Merdad Parsey and ...

Board of Directors announced today that, after a nationwide search, David Lubarsky, MD, MBA, FASA, will be the next President ...

Report with the AI impact on market trends - The global HVAC market size is estimated to grow by USD 74.02 billion from 2024 ...